vs
Side-by-side financial comparison of BillionToOne, Inc. (BLLN) and VICOR CORP (VICR). Click either name above to swap in a different company.
VICOR CORP is the larger business by last-quarter revenue ($113.0M vs $83.5M, roughly 1.4× BillionToOne, Inc.). VICOR CORP runs the higher net margin — 18.3% vs 6.8%, a 11.5% gap on every dollar of revenue. On growth, BillionToOne, Inc. posted the faster year-over-year revenue change (117.4% vs 20.2%).
BillionToOne, Inc. is a life sciences and molecular diagnostics firm developing high-precision genetic testing solutions. Its core offerings include non-invasive prenatal tests, oncology diagnostics, and rare disease screening, serving clinical providers and patients mainly in North America.
Vicor Corporation is a manufacturer of power modules headquartered in Andover, Massachusetts.
BLLN vs VICR — Head-to-Head
Income Statement — Q3 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $83.5M | $113.0M |
| Net Profit | $5.7M | $20.7M |
| Gross Margin | 69.9% | — |
| Operating Margin | 11.5% | 59.7% |
| Net Margin | 6.8% | 18.3% |
| Revenue YoY | 117.4% | 20.2% |
| Net Profit YoY | 138.3% | 713.9% |
| EPS (diluted) | $0.10 | $0.44 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $113.0M | ||
| Q4 25 | — | $107.3M | ||
| Q3 25 | $83.5M | $110.4M | ||
| Q2 25 | — | $96.0M | ||
| Q1 25 | — | $94.0M | ||
| Q4 24 | $45.1M | $96.2M | ||
| Q3 24 | $38.4M | $93.2M | ||
| Q2 24 | — | $85.9M |
| Q1 26 | — | $20.7M | ||
| Q4 25 | — | $46.5M | ||
| Q3 25 | $5.7M | $28.3M | ||
| Q2 25 | — | $41.2M | ||
| Q1 25 | — | $2.5M | ||
| Q4 24 | $-11.5M | $10.2M | ||
| Q3 24 | $-14.9M | $11.6M | ||
| Q2 24 | — | $-1.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | 55.4% | ||
| Q3 25 | 69.9% | 57.5% | ||
| Q2 25 | — | 95.9% | ||
| Q1 25 | — | 47.2% | ||
| Q4 24 | 57.1% | 52.4% | ||
| Q3 24 | 52.6% | 49.1% | ||
| Q2 24 | — | 49.8% |
| Q1 26 | — | 59.7% | ||
| Q4 25 | — | 14.6% | ||
| Q3 25 | 11.5% | 18.9% | ||
| Q2 25 | — | 47.3% | ||
| Q1 25 | — | -0.2% | ||
| Q4 24 | 17.0% | 9.6% | ||
| Q3 24 | -32.9% | 5.8% | ||
| Q2 24 | — | 0.2% |
| Q1 26 | — | 18.3% | ||
| Q4 25 | — | 43.4% | ||
| Q3 25 | 6.8% | 25.6% | ||
| Q2 25 | — | 42.9% | ||
| Q1 25 | — | 2.7% | ||
| Q4 24 | -25.5% | 10.7% | ||
| Q3 24 | -38.8% | 12.4% | ||
| Q2 24 | — | -1.4% |
| Q1 26 | — | $0.44 | ||
| Q4 25 | — | $1.01 | ||
| Q3 25 | $0.10 | $0.63 | ||
| Q2 25 | — | $0.91 | ||
| Q1 25 | — | $0.06 | ||
| Q4 24 | $-1.13 | $0.24 | ||
| Q3 24 | $-1.47 | $0.26 | ||
| Q2 24 | — | $-0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $195.2M | $404.2M |
| Total DebtLower is stronger | $55.0M | — |
| Stockholders' EquityBook value | $-239.5M | $754.1M |
| Total Assets | $327.5M | $804.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $404.2M | ||
| Q4 25 | — | $402.8M | ||
| Q3 25 | $195.2M | $362.4M | ||
| Q2 25 | — | $338.5M | ||
| Q1 25 | — | $296.1M | ||
| Q4 24 | $191.5M | $277.3M | ||
| Q3 24 | — | $267.6M | ||
| Q2 24 | — | $251.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $55.0M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $51.5M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $754.1M | ||
| Q4 25 | — | $711.6M | ||
| Q3 25 | $-239.5M | $630.1M | ||
| Q2 25 | — | $608.6M | ||
| Q1 25 | — | $580.3M | ||
| Q4 24 | $-251.7M | $570.1M | ||
| Q3 24 | $-242.9M | $554.6M | ||
| Q2 24 | — | $537.2M |
| Q1 26 | — | $804.9M | ||
| Q4 25 | — | $785.8M | ||
| Q3 25 | $327.5M | $710.2M | ||
| Q2 25 | — | $693.5M | ||
| Q1 25 | — | $665.0M | ||
| Q4 24 | $302.1M | $641.1M | ||
| Q3 24 | — | $632.8M | ||
| Q2 24 | — | $613.2M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $13.8M | — |
| Free Cash FlowOCF − Capex | $6.5M | — |
| FCF MarginFCF / Revenue | 7.7% | — |
| Capex IntensityCapex / Revenue | 8.8% | — |
| Cash ConversionOCF / Net Profit | 2.42× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $15.7M | ||
| Q3 25 | $13.8M | $38.5M | ||
| Q2 25 | — | $65.2M | ||
| Q1 25 | — | $20.1M | ||
| Q4 24 | — | $10.1M | ||
| Q3 24 | — | $22.6M | ||
| Q2 24 | — | $15.6M |
| Q1 26 | — | — | ||
| Q4 25 | — | $10.2M | ||
| Q3 25 | $6.5M | $34.5M | ||
| Q2 25 | — | $59.0M | ||
| Q1 25 | — | $15.6M | ||
| Q4 24 | — | $8.4M | ||
| Q3 24 | — | $14.1M | ||
| Q2 24 | — | $9.4M |
| Q1 26 | — | — | ||
| Q4 25 | — | 9.5% | ||
| Q3 25 | 7.7% | 31.2% | ||
| Q2 25 | — | 61.5% | ||
| Q1 25 | — | 16.6% | ||
| Q4 24 | — | 8.7% | ||
| Q3 24 | — | 15.2% | ||
| Q2 24 | — | 11.0% |
| Q1 26 | — | — | ||
| Q4 25 | — | 5.2% | ||
| Q3 25 | 8.8% | 3.6% | ||
| Q2 25 | — | 6.5% | ||
| Q1 25 | — | 4.8% | ||
| Q4 24 | — | 1.8% | ||
| Q3 24 | — | 9.1% | ||
| Q2 24 | — | 7.2% |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.34× | ||
| Q3 25 | 2.42× | 1.36× | ||
| Q2 25 | — | 1.58× | ||
| Q1 25 | — | 7.93× | ||
| Q4 24 | — | 0.99× | ||
| Q3 24 | — | 1.95× | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BLLN
| Prenatal | $74.1M | 89% |
| Oncology | $8.7M | 10% |
VICR
| Product revenue | $98.0M | 87% |
| Royalty revenue | $15.0M | 13% |
